Orexo Collaborates with Abera for Innovative Vaccine Development
Orexo AB (publ.) is taking significant steps in advancing its AmorphOX technology through a partnership with Abera Bioscience. This collaboration marks an exciting phase in developing mucosal vaccines leveraging Orexo's proprietary powder-based drug delivery platform.
About the Collaboration
The strategic alignment between Orexo and Abera has been crafted to broaden the applications of AmorphOX technology. Abera is renowned for its expertise in developing mucosal vaccines, providing a strong foundation for this collaboration. Together, they aim to create innovative solutions that improve vaccine stability and efficacy.
Advancing Vaccine Candidates
The collaboration focuses initially on creating powder-based intranasal vaccines, particularly targeting flu vaccine candidates. Intranasal vaccines offer a promising route for effectively reducing infection spread and could potentially play a crucial role in future pandemic preparedness.
Advantages of AmorphOX Technology
The AmorphOX platform enhances the properties of various active ingredients, including biologicals and small molecules. This technology's strengths lie in its ability to stabilize drugs, allowing for alternative and more effective delivery methods.
Voices from the Companies
Maria Alriksson, CEO of Abera, highlights the importance of this partnership: "Orexo’s profound knowledge of powder formulations aligns perfectly with our vaccine development expertise. The potential to address ongoing vaccine challenges is immense. We foresee significant advancements in the coming period.”
Funding and Support for Development
This collaboration is supported by previous grants from established bodies focused on epidemic preparedness, ensuring that the necessary resources are in place for research and development.
About Orexo
Orexo has spent over 30 years honing its craft in developing improved pharmaceuticals that cater to significant medical needs. In the U.S. market, they offer innovative treatments for opioid use disorders as well as other therapeutic areas. With reported net sales of SEK 639 million in a recent fiscal period, Orexo continues to expand its presence on the main list of Nasdaq Stockholm and is available as an ADR on OTCQX under the ticker ORXOY.
About Abera Bioscience
Abera, founded in 2012, brings together extensive research in molecular biology from leading institutions. The company specializes in vaccines characterized by rapid development times and cost efficiency. Their nasal vaccines are designed to tackle pressing health issues, including pandemic responsiveness, ensuring they remain at the forefront of vaccine innovation.
The BERA™ Vaccine Platform
Abera’s BERA™ platform utilizes bacterial particles decorated with specific antigens to create vaccines that are effective against diseases while minimizing transmission risks. This technology facilitates swift development cycles, ensuring that new vaccine candidates can be produced rapidly as needed.
Frequently Asked Questions
What is the main objective of the Orexo and Abera collaboration?
The collaboration aims to develop nasal powder vaccines using the AmorphOX technology to enhance the stability and efficacy of vaccine candidates.
What specific vaccine candidates is this partnership focusing on?
The initial focus is on intranasal vaccine candidates, specifically targeting influenza vaccines.
How does the AmorphOX technology benefit vaccine development?
AmorphOX technology improves the stability of active ingredients and enables effective alternative routes of drug administration, enhancing overall vaccine delivery.
Who is leading Abera Bioscience, and what is their background?
Maria Alriksson is the CEO of Abera, which has a strong foundation in molecular biology research and over 30 years of experience in vaccine development.
What makes Orexo significant in the pharmaceutical industry?
Orexo stands out due to its commitment to enhancing pharmaceuticals for serious medical needs, focusing on innovative treatments for opioid use disorder and collaborations like the one with Abera.
